.gif)
Avalyn Pharma Inc.
31
Recent developments include insider buying activity reported in May 2026 and the filing of the latest quarterly SEC 10-Q report in June 2026.
- Insider buying activity involving AVLN was reported on May 4, 2026, indicating insider engagement with the company [N1].
- Avalyn Pharma filed its quarterly 10-Q report on June 3, 2026, disclosing financial results and risk factors [S1].
Avalyn Pharma Inc. is a publicly traded company identified by ticker AVLN. The company’s latest SEC 10-Q filing dated June 3, 2026, provides detailed financial data for the quarter ended March 31, 2026. Avalyn Pharma holds substantial cash and short-term investments, resulting in strong liquidity ratios. The company reported a net loss and negative earnings per share for the quarter. Publicly available information does not specify the company’s sector, industry, or detailed business operations.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Avalyn Pharma Inc. reported a net loss of $26.87 million and negative earnings per share of $21.83 for the quarter ended March 31, 2026. The company maintains strong liquidity with a current ratio of 11.03 and a cash ratio of 10.45 as of the same date. Recent insider buying activity was reported in May 2026, reflecting insider engagement with the company [N1][S1].
Insider buying activity reported in May 2026 may indicate confidence from company insiders in Avalyn Pharma’s prospects. The company’s strong liquidity position provides a financial buffer to support ongoing operations or development activities. These factors could support operational continuity and potential value creation over time.
Avalyn Pharma reported a significant net loss and negative earnings per share for the latest quarter, indicating ongoing financial challenges. The lack of disclosed revenue and limited public information on business operations increases uncertainty about the company’s path to profitability. High liquidity ratios may reflect capital reserves but also highlight the absence of current revenue generation.
There is insufficient public information to assess Avalyn Pharma Inc.'s competitive advantages or moat. The company’s financial disclosures indicate strong liquidity but also ongoing net losses, which may reflect early-stage development or investment phases typical in pharmaceutical or biotech sectors.
• Financial Losses: The company reported a net loss of $26.87 million for the quarter ended March 31, 2026, which may impact its financial sustainability if losses continue.
• Limited Public Business Information: There is limited disclosure regarding Avalyn Pharma’s sector, industry, and detailed business model, which constrains visibility into its operational risks and opportunities.
• Dependence on Capital: Strong liquidity ratios suggest reliance on cash reserves and investments, which may be depleted if the company does not generate revenue or secure additional funding.
Business trends: The company maintains strong liquidity and has reported insider buying activity, indicating ongoing operational activity and insider interest.
Execution milestones: Recent SEC 10-Q filing provides updated financial disclosures and risk factor information.
Key risks: Continued net losses and limited public disclosure of business operations create uncertainty about financial sustainability and growth prospects.
Low visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Avalyn Pharma Inc. is a publicly traded company with ticker AVLN.
- As of 2026-03-31, the company reported cash and cash equivalents of $92.31 million and short-term investments of $30.82 million.
- Current assets totaled approximately $130.0 million, with current liabilities of about $11.79 million, resulting in a strong current ratio of 11.03 and a cash ratio of 10.45 as of 2026-03-31.
- The company reported a net loss of $26.87 million for the quarter ending 2026-03-31, with basic and diluted earnings per share of -$21.83.
- Recent news includes insider buying activity reported on May 4, 2026, indicating insider confidence or interest in the company [N1].
- The latest SEC filing is a 10-Q form filed on June 3, 2026, which includes risk factors disclosures [S1].
Generated 2026-06-03
- S1 | 2026-06-03 | 10-Q
- N1 | 2026-05-04 | www.nasdaq.com | Monday 5/4 Insider Buying Report: AVLN, CSGP | https://www.nasdaq.com/articles/monday-5-4-insider-buying-report-avln-csgp
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine